A new generation of high potency allergen bioparticles
Guy Tropper, Véronique Gomord, Anne-Catherine Fitchette and 7 more
World Allergy Organization Journal · 2020
doi:10.1016/j.waojou.2020.100142 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Current allergen products carry significant limits in terms of their quality and consistency and this likely accounts for their shortcomings in the clinical diagnosis of allergy and its treatment through desensitization. Increasingly, stakeholders (clinicians, the pharmaceutical industry and regulatory agencies) are seeking better, more effective products aligned with the principles of Precision Medicine.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.